GLP1-Sema and GLP-1 SM terminology, semaglutide research, original references and batch-specific COA verification.
Research reference · Updated October 23, 2026
Published by Disguised Alpha · Laboratory research use only
Quick answer. GLP1-Sema is informal catalog shorthand associated with semaglutide, a GLP-1 receptor agonist. Disguised Alpha lists this research category as GLP-1 SM. The catalog name is not a batch identity result: use the selected product record and matching certificate of analysis to evaluate the supplied material.
Scientific context: original research publication. Supplier records: GLP-1 SM catalog and batch COAs.
Disguised Alpha uses GLP-1 SM as a catalog label. “Sema” is an informal abbreviation for semaglutide. In the literature, semaglutide is a modified GLP-1 analogue studied as a GLP-1 receptor agonist. “GLP-1” alone can refer to the endogenous hormone or a broader research area; it is not a complete identifier for a supplied material.
| Term | How to interpret it |
|---|---|
| GLP1 Sema / GLP-1 Sema | Common search shorthand. Confirm the compound and formulation stated by the source. |
| GLP-1 SM | The Disguised Alpha catalog label. Match the chosen option with its lot documentation. |
| Semaglutide | The scientific compound name used to locate relevant publications. |
| GLP-1R | The receptor discussed in semaglutide’s pharmacology; a receptor name is not a batch identity result. |
Lau et al., 2015: Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide describes the discovery work and chemical modifications used to develop semaglutide. It is a useful primary source for understanding how the analogue differs from native GLP-1.
When reading a paper, separate chemical identity, receptor activity, experimental exposure and the measured endpoint. A result from one preparation or study model cannot automatically be transferred to another formulation. Keep a record of the paper, its methods, the reference material and the limitations relevant to your experiment.
Semaglutide’s GLP-1 receptor focus differs from the GIP/GLP-1 receptor profile examined in tirzepatide studies. The GLP2-Tirz reference explains that terminology and links to primary studies. The GLP3 reference explains informal triple-agonist naming. These labels should not be treated as a numerical ranking of strength, quality or suitability.
Start with the selected catalog option, the lot printed on the item and the matching report in the COA portal. Compare the sample identifier, compound identity, method, units and report date. A purity percentage is not the same measurement as the quantity in a container. Do not assume an unreported test was performed.
Retain the original report with your laboratory records. A publication about a compound does not verify a supplier’s batch, and a report for one lot does not establish the properties of another. For a missing or mismatched record, contact Disguised Alpha before relying on it.
Use the GLP-1 SM product page for current catalog options and the COA portal for available lot reports. Check the exact preparation listed; a shared compound name alone does not establish equivalent composition or analytical results.
The Research Hub provides related references, while quality documentation explains the supplier’s stated process.
No. GLP-1 can name the natural hormone or the receptor research field. Semaglutide identifies a particular analogue. Use the full compound name when searching the literature.
No. It provides scientific context for the study material. Evaluation of a supplied lot depends on that lot’s documentation and testing.
No. This is a laboratory research reference and provides no treatment, dosing or administration guidance.
Published by Disguised Alpha, a supplier of laboratory research materials. Editorial standards. Research use only; not for human or veterinary use. This reference provides no dosing, administration or treatment instructions.